晚期非小细胞肺癌两种一线化疗方案的疗效观察和药物经济学分析

目的 探讨晚期非小细胞肺癌（NSCLC）不同治疗方案的临床疗效和经济学效果，指导临床合理用药。方法 收集南京市胸科医院2015年1月-2016年12月符合要求的晚期NSCLC患者56例，通过随机数进行随机化分为培美曲塞+顺铂（PP组）30例和吉西他滨+顺铂（GP组）26例，观察两组治疗效果并对成本与效果进行回顾性分析。结果 PP组和GP组化疗方案的有效率分别为46.67%和42.31%，差异无统计学意义；PP组不良反应发生率与GP组存在显著统计学差异（P<0.05）；两组平均费用分别为31 985.48元和27 683.15元。PP组的平均住院天数（10.94 d）少于GP组（13.91 d）。与GP组相比，PP组每增加1个效果单位需要多投入的成本为986.77元。结论 从成本效果分析，PP组的化疗费用较高，但是安全性好于GP组。

Therapeutic observation and pharmacoeconomic analysis of two first-line chemotherapy regimens in advanced NSCLC

Objective To evaluate the cost-effectiveness of two chemotherapy regimens in NSCLC for the purpose of lower cost, higher quality medical care. Methods 56 patients with advanced NSCLC were divided into two groups from our hospital, group PP (pemtrexal+cisplatin, n=30) and group GP (gemcitabine+cisplatin, n=26), and analyzed by pharmacoeconomic cost-effectiveness method, and retrospective analysis was also applied. Results Effective rates of two regimens were 46.67%, 42.31%, no significant difference. But there was significant difference in the incidence rate of ADR between the two groups. The cost of chemotherapy regiments were 31 985.48 and 27 683.15 yuan. The average length of stay was 10.94 and 13.91 days. Compared to group GP, for each unit of efficacy, the cost in group PP were increased 986.77 yuan. Conclusion From the analysis of cost-effectiveness, group PP had higher chemotherapy costs, but better safety than group GP.